Drug Approval | March 28, 2026
Alembic receives USFDA final approval for Paroxetine Extended-Release Tablets
Paroxetine extended-release tablets are indicated for the treatment of major depressive disorder
Paroxetine extended-release tablets are indicated for the treatment of major depressive disorder
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes
Since launching, the hospital has performed over 40 intestinal transplants, including 21 in 2025 alone
The programme aims to provide critical healthcare services to approximately 4 lakh people in remote and resource-scarce communities
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
Subscribe To Our Newsletter & Stay Updated
